Article thumbnail

Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004

By Fei-Yuan Hsiao, Yi-Wen Tsai and Weng-Foung Huang
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2918598
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). Bloor K: Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood)
  2. (2000). Chao LW: Does regulation drive out competition in pharmaceutical markets.
  3. (1998). Comanor WS: Strategic pricing of new pharmaceuticals. Rev Econ Stat
  4. (2003). Diffusion of Innovations
  5. (2004). Drug spending in Canada: recent trends and causes. Med Care
  6. (2005). Health Insurance: The National Health Insurance Statistics.
  7. (2004). Innovation and diffusion National Bureau of Economic Research (NBER) working paper no.10212
  8. (2004). JK: National health insurance and technology adoption: evidence from Taiwan. Contemporary Economic Policy
  9. (2005). Learning the value of drugs: is rofecoxib a regulatory success story?
  10. (2005). OECD: Health at a Glance: OECD Indicators
  11. (2002). Phibbs CS: Managed care, technology adoption, and health care: the adoption of neonatal intensive care.
  12. (2002). Quantifying components of drug expenditure inflation: the British Columbia seniors’ drug benefit plan. Health Serv Res
  13. (1996). SB: Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan,
  14. (2002). Segmented regression analysis of interrupted time series studies in medication use research.
  15. (1998). SK: Managed care and technology diffusion: the Case of MRI. Health Aff (Millwood)
  16. (2008). Sloan FA: Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost-effective? Value Health
  17. (2004). The impact of drug coverage on COX-2 inhibitor use in Medicare. Health Aff (Millwood)
  18. (2001). The impact of pipeline drugs on drug spending growth. Health Aff (Millwood)
  19. (2001). The U.S. pharmaceutical industry: why major growth in times of cost containment? Health Aff (Millwood)
  20. WHO Collaborating Centre for Drug Statistics Methodology: The ATC and DDD
  21. (2004). Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics